Shares of Heat Biologics Inc. (NASDAQ:HTBX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus target price of $5.38 for the company and are expecting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given Heat Biologics an industry rank of 82 out of 265 based on the ratings given to related companies.
Several analysts have recently commented on HTBX shares. Roth Capital started coverage on shares of Heat Biologics in a research report on Monday, June 20th. They set a “buy” rating and a $2.75 price target on the stock. Zacks Investment Research raised shares of Heat Biologics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Friday, August 19th. Finally, Noble Financial reaffirmed a “buy” rating and set a $8.00 price target on shares of Heat Biologics in a research report on Wednesday, August 17th.
Shares of Heat Biologics (NASDAQ:HTBX) traded down 2.81% on Wednesday, reaching $1.35. The company’s stock had a trading volume of 165,952 shares. The firm’s market capitalization is $26.31 million. Heat Biologics has a one year low of $0.40 and a one year high of $4.98. The firm has a 50-day moving average price of $1.48 and a 200 day moving average price of $0.90.
Heat Biologics (NASDAQ:HTBX) last released its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.10. On average, analysts anticipate that Heat Biologics will post ($0.76) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Heat Biologics stock. Sabby Management LLC boosted its position in shares of Heat Biologics Inc. (NASDAQ:HTBX) by 4,005.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 902,007 shares of the biopharmaceutical company’s stock after buying an additional 880,036 shares during the period. Sabby Management LLC owned about 10.71% of Heat Biologics worth $626,000 as of its most recent SEC filing. 8.62% of the stock is currently owned by institutional investors.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.